PUL		WVTT		Utility	Mean Time to Recovery (Days)
	0-3 Months	4-12 Months	0-3 Months	4-12 Months
Mean IPSS (SD)*	22.2 (5.5)[@55440]	11.5 (7.3)[@55442]	22.0 (4.8)[@55441]	10.3 (6.7)[@55443]	0.99 for mild LUTS[@55449] 0.90 for moderate LUTS[@55449] 0.79 for severe LUTS[@55449]	NA
Post-Procedure Catheterization	51.4%[@55440]	NA	90.4%[@55441]	NA	-0.05[@55451]	0.9 for PUL[@55440] 3.4 for WVTT[@55441]
Adverse Events
Bladder Spasm	3.6%[@55440]	0.7%[@55440]	NA	NA	-0.06[@55452]	30.0‡‡
Urinary Retention	0.7%[@55440]	0.7%[@55440]	3.7%[@55441]	0.0%[@55441]	-0.18[@55452]	30.7‡
Urinary Tract Infection	2.9%[@55440]	0.0%[@55440]	3.7%[@55441]	0.0%[@55441]	-0.07[@55452]	13.3‡
Pelvic Pain	17.9%[@55440]	1.4%[@55440]	2.9%[@55441]	0.0%[@55441]	-0.03**	72.5‡
Hematuria	25.7%[@55440]	0.7%[@55440]	11.8%[@55441]	0.0%[@55441]	-0.20†	25.9‡
Dysuria	34.3%[@55440]	0.7%[@55440]	16.9%[@55441]	0.7%[@55441]	-0.03[@55452]	38.2‡
Urinary Urge Incontinence	3.6%[@55440]	0.7%[@55440]	0.0%[@55441]	0.0%[@55441]	-0.20[@55452]	30.0‡
Frequency and Urgency	7.1%[@55440]	2.1%[@55440]	5.9%[@55441]	0.0%[@55441]	-0.03**	53.2‡
Encrusted Implants	7.1%[@55440]		NA	NA	-0.03††	30.0‡‡
Retreatment Type
PUL	21.9%[@55442]		NA		-0.03††	30.0‡‡
WVTT	NA		15.4%[@55443]		-0.03††	30.0‡‡
BPH Medical Therapy	40.6%[@55442]		53.8%[@55443]		-0.03[@55452]	30.0‡‡
TURP	37.5%[@55442]		23.1%[@55443]		-0.05[@55452]	30.0‡‡
Open Prostatectomy	0.0%[@55442]		7.7%[@55443]		-0.16[@55453]	30.0‡‡